ES2360283T3 - Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf. - Google Patents

Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf. Download PDF

Info

Publication number
ES2360283T3
ES2360283T3 ES02787595T ES02787595T ES2360283T3 ES 2360283 T3 ES2360283 T3 ES 2360283T3 ES 02787595 T ES02787595 T ES 02787595T ES 02787595 T ES02787595 T ES 02787595T ES 2360283 T3 ES2360283 T3 ES 2360283T3
Authority
ES
Spain
Prior art keywords
formula
compound
tautomer
acid amide
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02787595T
Other languages
English (en)
Spanish (es)
Inventor
Guido Bold
Pascal Furet
Paul William Manley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Application granted granted Critical
Publication of ES2360283T3 publication Critical patent/ES2360283T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES02787595T 2001-11-08 2002-11-07 Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf. Expired - Lifetime ES2360283T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0126902 2001-11-08
GBGB0126902.6A GB0126902D0 (en) 2001-11-08 2001-11-08 Organic compounds

Publications (1)

Publication Number Publication Date
ES2360283T3 true ES2360283T3 (es) 2011-06-02

Family

ID=9925448

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02787595T Expired - Lifetime ES2360283T3 (es) 2001-11-08 2002-11-07 Amidas de ácido antralínico y su uso como inhibidores de tirosina quisina receptora de vegf.

Country Status (28)

Country Link
US (2) US7091224B2 (enExample)
EP (1) EP1446382B1 (enExample)
JP (1) JP2005511602A (enExample)
KR (1) KR100602977B1 (enExample)
CN (1) CN1300113C (enExample)
AT (1) ATE496889T1 (enExample)
AU (1) AU2002351909B2 (enExample)
BR (1) BR0213970A (enExample)
CA (1) CA2463968C (enExample)
CO (1) CO5580823A2 (enExample)
DE (1) DE60239073D1 (enExample)
ES (1) ES2360283T3 (enExample)
GB (1) GB0126902D0 (enExample)
HR (1) HRP20040411A2 (enExample)
IL (1) IL161747A0 (enExample)
MX (1) MXPA04004391A (enExample)
NO (1) NO327231B1 (enExample)
NZ (1) NZ532590A (enExample)
PE (1) PE20030714A1 (enExample)
PL (1) PL368416A1 (enExample)
PT (1) PT1446382E (enExample)
RU (1) RU2318811C2 (enExample)
SA (1) SA02230412B1 (enExample)
TW (1) TWI260222B (enExample)
UA (1) UA77446C2 (enExample)
WO (1) WO2003040102A1 (enExample)
YU (1) YU36004A (enExample)
ZA (1) ZA200402940B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
DE10327719A1 (de) * 2003-06-13 2005-01-20 Schering Ag VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en) 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1820795A4 (en) 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN101265274B (zh) * 2007-02-16 2013-09-04 中国医学科学院药物研究所 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
AR073216A1 (es) 2008-08-27 2010-10-20 Leo Pharma As Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en) 2013-06-21 2014-02-05 Immusmol Sas Method for detecting small molecules in a sample
CN107954893A (zh) * 2017-11-28 2018-04-24 兰州纬寰生物科技有限公司 邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0850222B1 (en) * 1996-06-29 2003-05-28 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20030714A1 (es) 2003-10-13
MXPA04004391A (es) 2005-12-12
KR20050044382A (ko) 2005-05-12
HRP20040411A2 (en) 2005-04-30
JP2005511602A (ja) 2005-04-28
NO327231B1 (no) 2009-05-18
BR0213970A (pt) 2004-08-31
US7091224B2 (en) 2006-08-15
RU2318811C2 (ru) 2008-03-10
UA77446C2 (en) 2006-12-15
RU2004117543A (ru) 2006-01-10
CA2463968C (en) 2011-02-22
CO5580823A2 (es) 2005-11-30
CN1300113C (zh) 2007-02-14
GB0126902D0 (en) 2002-01-02
US7482369B2 (en) 2009-01-27
TW200300087A (en) 2003-05-16
ZA200402940B (en) 2005-02-10
CA2463968A1 (en) 2003-05-15
SA02230412B1 (ar) 2007-07-31
KR100602977B1 (ko) 2006-07-20
NZ532590A (en) 2005-12-23
YU36004A (sh) 2006-08-17
TWI260222B (en) 2006-08-21
NO20042187L (no) 2004-05-26
US20060178409A1 (en) 2006-08-10
DE60239073D1 (de) 2011-03-10
EP1446382A1 (en) 2004-08-18
PT1446382E (pt) 2011-05-03
IL161747A0 (en) 2005-11-20
WO2003040102A1 (en) 2003-05-15
US20050096356A1 (en) 2005-05-05
EP1446382B1 (en) 2011-01-26
PL368416A1 (en) 2005-03-21
CN1585750A (zh) 2005-02-23
AU2002351909B2 (en) 2007-04-26
ATE496889T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
RU2286338C2 (ru) N-ариламиды антраниловой кислоты и тиоантраниловой кислоты
US7091224B2 (en) Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
PT1259487E (pt) Derivados de 2-amino-nicotinamida e as suas utilizações como inibidores de receptores vegf de tirosina quinase
AU2002351909A1 (en) Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors
CN114269720A (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
US7067543B2 (en) Anthranilic acid amides and pharmaceutical use thereof
ES2324531T3 (es) Derivados de amida del acido antranilico y su uso farmaceutico.
ES2359395T3 (es) Amidas de acido antranílico y su uso farmacéutico.
ZA200402623B (en) Anthranillic acid amides and pharmaceutical use thereof
NZ543915A (en) Anthranilic acid amides for use in retinopathy or neoplastic disease, and their process of preparation